Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer
May 14, 2024 01:15 ET
|
Nykode Therapeutics ASA
OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Oncolytic Virus Therapy Market Size Clinical Trials Sales Forecast 2030
May 14, 2024 01:08 ET
|
KuicK Research
Delhi, May 14, 2024 (GLOBE NEWSWIRE) -- Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030 Report Highlights: Global Oncolytic Virus Immunotherapy Therapy...
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
May 13, 2024 20:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a...
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
May 13, 2024 20:00 ET
|
HUTCHMED (China) Limited
— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED’s...
New Poll: Overwhelming Voter Support in North Carolina for the Physician Assistant Licensure Compact
May 13, 2024 18:14 ET
|
North Carolina Academy of Physician Assistants
Durham, NC, May 13, 2024 (GLOBE NEWSWIRE) -- New research shows a vast majority of North Carolina voters support policies that expand access to health care. By large majorities and on a bipartisan...
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
May 13, 2024 16:45 ET
|
Ikena Oncology, Inc.
Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS...
A Pint for Kim Blood Drive Breaks State Record Fifth Year in a Row with More than 700 Donors Showing Up to Give Blood
May 13, 2024 14:43 ET
|
A Pint for Kim
NAPERVILLE, Ill., May 13, 2024 (GLOBE NEWSWIRE) -- A Pint For Kim, a national grassroots movement created in 2020 in honor of mom Kimberly Sandford who lost her eight-year battle with a rare cancer,...
Claritas HealthTech Further Expands Global Presence with Entry into Brazil Focusing on its Solutions in Nuclear Medicine
May 13, 2024 14:40 ET
|
Claritas HealthTech Ltd
LONDON and NEW YORK and SAO PAULO, Brazil, May 13, 2024 (GLOBE NEWSWIRE) -- Claritas HealthTech (“Claritas”), a healthcare technology company specializing in advanced medical image enhancement,...
Hometown Hero Establishes Texas Hemp Business Council
May 13, 2024 14:22 ET
|
Hometown Hero CBD
AUSTIN, Texas, May 13, 2024 (GLOBE NEWSWIRE) -- Hometown Hero, the veteran-supporting cannabusiness of hemp-derived THC and cannabidiol-based products, today announced the formation of the Texas...
SPR® Therapeutics Announces Publication of Study Providing Evidence of the Impact of SPRINT® PNS Treatment in Relieving Postoperative Knee Pain
May 13, 2024 14:16 ET
|
SPR Therapeutics, Inc.
Publication of study provides evidence of the impact of SPRINT PNS in relieving post-operative knee pain after total knee arthroplasty (TKA).